Tabrecta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic, non-small cell lung cancer whose tumors have a mutation known as mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. Tabrecta is also referred to by its drug name, capmatinib.
Tabrecta is a member of a class of drugs called tyrosine kinase inhibitors. Tabrecta is believed to work by inhibiting the activity of MET kinases, which are involved in the proliferation (increase) of tumors. Inhibiting the activity of MET results in the slowing of cancer cell replication.
How do I take it?
Prescribing information states that Tabrecta is taken orally as a tablet twice daily.
Tabrecta should be taken exactly as prescribed by a physician.
The FDA-approved label for Tabrecta lists common side effects including peripheral edema (swelling), nausea, fatigue, vomiting, shortness of breath, and decreased appetite.
Rare but serious side effects listed for Tabrecta include high sensitivity to sunlight, liver damage, fetal harm, and interstitial lung disease (scarring of the lungs).
For more details about this treatment, visit:
Novartis — Tabrecta
Capmatinib (Oral Route) — Mayo Clinic